User login
Acne take home messages from the AAD annual meeting
WASHINGTON – In an interview at the close of the annual meeting of the American Academy of Dermatology, .
Both Dr. Harper, who practices in Birmingham, Ala., and is the immediate past president of the American Acne & Rosacea Society, and Dr. Keri, of the department of dermatology at the University of Miami and the Miami VA Healthcare System, spoke during several acne sessions. Among the topics they discussed during the interview were a relatively recent meta-analysis that provides reassuring information about depression and isotretinoin, how to start patients on spironolactone, and the use of antibiotics – and benzoyl peroxide.
[embed:render:related:node:193178]
They emphasized the importance of not withholding treatment for patients who need it and the psychosocial impact of acne. “Patients need to get to the treatment they need ... faster,” Dr. Harper said. “We want to treat sooner, and we want to prevent scarring,” Dr. Keri added.
Dr. Keri disclosed relationships with Hoffmann–La Roche, Ortho Dermatologics, and Pierre Fabre Dermatologie. Dr. Harper has no relevant financial disclosures.
WASHINGTON – In an interview at the close of the annual meeting of the American Academy of Dermatology, .
Both Dr. Harper, who practices in Birmingham, Ala., and is the immediate past president of the American Acne & Rosacea Society, and Dr. Keri, of the department of dermatology at the University of Miami and the Miami VA Healthcare System, spoke during several acne sessions. Among the topics they discussed during the interview were a relatively recent meta-analysis that provides reassuring information about depression and isotretinoin, how to start patients on spironolactone, and the use of antibiotics – and benzoyl peroxide.
[embed:render:related:node:193178]
They emphasized the importance of not withholding treatment for patients who need it and the psychosocial impact of acne. “Patients need to get to the treatment they need ... faster,” Dr. Harper said. “We want to treat sooner, and we want to prevent scarring,” Dr. Keri added.
Dr. Keri disclosed relationships with Hoffmann–La Roche, Ortho Dermatologics, and Pierre Fabre Dermatologie. Dr. Harper has no relevant financial disclosures.
WASHINGTON – In an interview at the close of the annual meeting of the American Academy of Dermatology, .
Both Dr. Harper, who practices in Birmingham, Ala., and is the immediate past president of the American Acne & Rosacea Society, and Dr. Keri, of the department of dermatology at the University of Miami and the Miami VA Healthcare System, spoke during several acne sessions. Among the topics they discussed during the interview were a relatively recent meta-analysis that provides reassuring information about depression and isotretinoin, how to start patients on spironolactone, and the use of antibiotics – and benzoyl peroxide.
[embed:render:related:node:193178]
They emphasized the importance of not withholding treatment for patients who need it and the psychosocial impact of acne. “Patients need to get to the treatment they need ... faster,” Dr. Harper said. “We want to treat sooner, and we want to prevent scarring,” Dr. Keri added.
Dr. Keri disclosed relationships with Hoffmann–La Roche, Ortho Dermatologics, and Pierre Fabre Dermatologie. Dr. Harper has no relevant financial disclosures.
Immunomodulators for pediatric skin diseases
WASHINGTON – At the annual meeting of the American Academy of Dermatology, colleagues A. Yasmine Kirkorian, MD, a pediatric dermatologist at George Washington University, Washington, and interim chief of pediatric dermatology at Children’s National Health System, and Adam Friedman, MD, professor and interim chair of dermatology at the university, sat down with Dermatology News and discussed their presentations at a session on the use of immunomodulators for inflammatory and neoplastic skin diseases.
In this video, , with her clinical pearls and practical considerations for treating atopic dermatitis, psoriasis, and hidradenitis suppurativa in pediatric patients, covering both on- and off-label treatments.
“Children sometimes require systemic treatment and we shouldn’t hold it back from them because of their age; if they’re severely ill ... they need to be treated,” she said, summing up one of her main points.
During the interview immediately after the AAD meeting, she mentioned dupilumab, which was approved by the Food and Drug Administration for treatment of moderate to severe AD in patients aged 12-17 years.
Dr. Friedman and Dr. Kirkorian reported having no financial disclosures.
WASHINGTON – At the annual meeting of the American Academy of Dermatology, colleagues A. Yasmine Kirkorian, MD, a pediatric dermatologist at George Washington University, Washington, and interim chief of pediatric dermatology at Children’s National Health System, and Adam Friedman, MD, professor and interim chair of dermatology at the university, sat down with Dermatology News and discussed their presentations at a session on the use of immunomodulators for inflammatory and neoplastic skin diseases.
In this video, , with her clinical pearls and practical considerations for treating atopic dermatitis, psoriasis, and hidradenitis suppurativa in pediatric patients, covering both on- and off-label treatments.
“Children sometimes require systemic treatment and we shouldn’t hold it back from them because of their age; if they’re severely ill ... they need to be treated,” she said, summing up one of her main points.
During the interview immediately after the AAD meeting, she mentioned dupilumab, which was approved by the Food and Drug Administration for treatment of moderate to severe AD in patients aged 12-17 years.
Dr. Friedman and Dr. Kirkorian reported having no financial disclosures.
WASHINGTON – At the annual meeting of the American Academy of Dermatology, colleagues A. Yasmine Kirkorian, MD, a pediatric dermatologist at George Washington University, Washington, and interim chief of pediatric dermatology at Children’s National Health System, and Adam Friedman, MD, professor and interim chair of dermatology at the university, sat down with Dermatology News and discussed their presentations at a session on the use of immunomodulators for inflammatory and neoplastic skin diseases.
In this video, , with her clinical pearls and practical considerations for treating atopic dermatitis, psoriasis, and hidradenitis suppurativa in pediatric patients, covering both on- and off-label treatments.
“Children sometimes require systemic treatment and we shouldn’t hold it back from them because of their age; if they’re severely ill ... they need to be treated,” she said, summing up one of her main points.
During the interview immediately after the AAD meeting, she mentioned dupilumab, which was approved by the Food and Drug Administration for treatment of moderate to severe AD in patients aged 12-17 years.
Dr. Friedman and Dr. Kirkorian reported having no financial disclosures.
SPD president discusses pediatric research, and more
WASHINGTON – in an interview at the annual meeting of the American Academy of Dermatology.
Dr. Davis, a pediatric dermatologist at the Mayo Clinic, Rochester, Minn., said that the SPD had a strategic retreat prior to the AAD annual meeting to look at goals attained over the last 3 years “and where we’re going for the next 3 years.” Goals that have been accomplished “move us forward as a society for patient advocacy, specialty advocacy, workforce strengthening, research advancement, patient care, and education,” she noted. The education arena, for example, includes not only educating patients and their families, so they can get the best health care possible, “but we want to educate the pipeline of trainees coming through medical school so ... they have exposure to pediatric dermatology and they can hopefully develop an interest in pediatric dermatology as a future career.”
The SPD now has more than 1,200 members, and has a research arm, the Pediatric Dermatology Research Alliance (PeDRA), which has multiple projects, the largest of which is looking at the stigma of skin diseases, a study that involves patients with severe skin diseases and their families, said Dr. Davis. Watch the video above for more on PeDRA and SPD.
Dr. Davis disclosed that she is involved in a study for Regeneron but has not received any personal financial compensation.
WASHINGTON – in an interview at the annual meeting of the American Academy of Dermatology.
Dr. Davis, a pediatric dermatologist at the Mayo Clinic, Rochester, Minn., said that the SPD had a strategic retreat prior to the AAD annual meeting to look at goals attained over the last 3 years “and where we’re going for the next 3 years.” Goals that have been accomplished “move us forward as a society for patient advocacy, specialty advocacy, workforce strengthening, research advancement, patient care, and education,” she noted. The education arena, for example, includes not only educating patients and their families, so they can get the best health care possible, “but we want to educate the pipeline of trainees coming through medical school so ... they have exposure to pediatric dermatology and they can hopefully develop an interest in pediatric dermatology as a future career.”
The SPD now has more than 1,200 members, and has a research arm, the Pediatric Dermatology Research Alliance (PeDRA), which has multiple projects, the largest of which is looking at the stigma of skin diseases, a study that involves patients with severe skin diseases and their families, said Dr. Davis. Watch the video above for more on PeDRA and SPD.
Dr. Davis disclosed that she is involved in a study for Regeneron but has not received any personal financial compensation.
WASHINGTON – in an interview at the annual meeting of the American Academy of Dermatology.
Dr. Davis, a pediatric dermatologist at the Mayo Clinic, Rochester, Minn., said that the SPD had a strategic retreat prior to the AAD annual meeting to look at goals attained over the last 3 years “and where we’re going for the next 3 years.” Goals that have been accomplished “move us forward as a society for patient advocacy, specialty advocacy, workforce strengthening, research advancement, patient care, and education,” she noted. The education arena, for example, includes not only educating patients and their families, so they can get the best health care possible, “but we want to educate the pipeline of trainees coming through medical school so ... they have exposure to pediatric dermatology and they can hopefully develop an interest in pediatric dermatology as a future career.”
The SPD now has more than 1,200 members, and has a research arm, the Pediatric Dermatology Research Alliance (PeDRA), which has multiple projects, the largest of which is looking at the stigma of skin diseases, a study that involves patients with severe skin diseases and their families, said Dr. Davis. Watch the video above for more on PeDRA and SPD.
Dr. Davis disclosed that she is involved in a study for Regeneron but has not received any personal financial compensation.
REPORTING FROM AAD 2019
Climbing the therapeutic ladder in eczema-related itch
WASHINGTON – Currently available including antihistamines and an oral antiemetic approved for preventing chemotherapy-related nausea and vomiting, Peter Lio, MD, said at a symposium presented by the Coalition United for Better Eczema Care (CUBE-C).
There are four basic areas of treatment, which Dr. Lio, a dermatologist at Northwestern University, Chicago, referred to as the “itch therapeutic ladder.” In a video interview at the meeting, he reviewed the treatments, starting with topical therapies, which include camphor and menthol, strontium-containing topicals, as well as “dilute bleach-type products” that seem to have some anti-inflammatory and anti-itch effects.
The next levels: oral medications – antihistamines, followed by “more intense” options that may carry more risks, such as the antidepressant mirtazapine, and aprepitant, a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting. Gabapentin and naltrexone can also be helpful for certain populations; all are used off-label, he pointed out.
Dr. Lio, formally trained in acupuncture, often uses alternative therapies as the fourth rung of the ladder. These include using a specific acupressure point, which he said “seems to give a little bit of relief.”
In the interview, he also discussed considerations in children with atopic dermatitis and exciting treatments in development, such as biologics that target “one of the master itch cytokines,” interleukin-31.
“Itch is such an important part of this disease because we know not only is it one of the key pieces that pushes the disease forward and keeps these cycles going, but also contributes a huge amount to the morbidity,” he said.
CUBE-C, established by the National Eczema Association (NEA), is a “network of cross-specialty leaders, patients and caregivers, constructing an educational curriculum based on standards of effective treatment and disease management,” according to the NEA.
The symposium was supported by an educational grant from Sanofi Genzyme, Regeneron Pharmaceuticals, and Pfizer. Dr. Lio reported serving as a speaker, consultant, and/or advisor for companies developing and marketing atopic dermatitis therapies and products.
WASHINGTON – Currently available including antihistamines and an oral antiemetic approved for preventing chemotherapy-related nausea and vomiting, Peter Lio, MD, said at a symposium presented by the Coalition United for Better Eczema Care (CUBE-C).
There are four basic areas of treatment, which Dr. Lio, a dermatologist at Northwestern University, Chicago, referred to as the “itch therapeutic ladder.” In a video interview at the meeting, he reviewed the treatments, starting with topical therapies, which include camphor and menthol, strontium-containing topicals, as well as “dilute bleach-type products” that seem to have some anti-inflammatory and anti-itch effects.
The next levels: oral medications – antihistamines, followed by “more intense” options that may carry more risks, such as the antidepressant mirtazapine, and aprepitant, a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting. Gabapentin and naltrexone can also be helpful for certain populations; all are used off-label, he pointed out.
Dr. Lio, formally trained in acupuncture, often uses alternative therapies as the fourth rung of the ladder. These include using a specific acupressure point, which he said “seems to give a little bit of relief.”
In the interview, he also discussed considerations in children with atopic dermatitis and exciting treatments in development, such as biologics that target “one of the master itch cytokines,” interleukin-31.
“Itch is such an important part of this disease because we know not only is it one of the key pieces that pushes the disease forward and keeps these cycles going, but also contributes a huge amount to the morbidity,” he said.
CUBE-C, established by the National Eczema Association (NEA), is a “network of cross-specialty leaders, patients and caregivers, constructing an educational curriculum based on standards of effective treatment and disease management,” according to the NEA.
The symposium was supported by an educational grant from Sanofi Genzyme, Regeneron Pharmaceuticals, and Pfizer. Dr. Lio reported serving as a speaker, consultant, and/or advisor for companies developing and marketing atopic dermatitis therapies and products.
WASHINGTON – Currently available including antihistamines and an oral antiemetic approved for preventing chemotherapy-related nausea and vomiting, Peter Lio, MD, said at a symposium presented by the Coalition United for Better Eczema Care (CUBE-C).
There are four basic areas of treatment, which Dr. Lio, a dermatologist at Northwestern University, Chicago, referred to as the “itch therapeutic ladder.” In a video interview at the meeting, he reviewed the treatments, starting with topical therapies, which include camphor and menthol, strontium-containing topicals, as well as “dilute bleach-type products” that seem to have some anti-inflammatory and anti-itch effects.
The next levels: oral medications – antihistamines, followed by “more intense” options that may carry more risks, such as the antidepressant mirtazapine, and aprepitant, a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting. Gabapentin and naltrexone can also be helpful for certain populations; all are used off-label, he pointed out.
Dr. Lio, formally trained in acupuncture, often uses alternative therapies as the fourth rung of the ladder. These include using a specific acupressure point, which he said “seems to give a little bit of relief.”
In the interview, he also discussed considerations in children with atopic dermatitis and exciting treatments in development, such as biologics that target “one of the master itch cytokines,” interleukin-31.
“Itch is such an important part of this disease because we know not only is it one of the key pieces that pushes the disease forward and keeps these cycles going, but also contributes a huge amount to the morbidity,” he said.
CUBE-C, established by the National Eczema Association (NEA), is a “network of cross-specialty leaders, patients and caregivers, constructing an educational curriculum based on standards of effective treatment and disease management,” according to the NEA.
The symposium was supported by an educational grant from Sanofi Genzyme, Regeneron Pharmaceuticals, and Pfizer. Dr. Lio reported serving as a speaker, consultant, and/or advisor for companies developing and marketing atopic dermatitis therapies and products.
VIDEO: Select atopic dermatitis patients need patch testing
SAN DIEGO – Patch testing may be in order for some patients with atopic dermatitis, according to Jonathan Silverberg, MD, PhD, of the department of dermatology, Northwestern University, Chicago.
Allergic contact dermatitis is a common comorbid condition in people with AD “and sometimes, can flare up the severity of the disease,” he said in a video interview at the American Academy of Dermatology annual meeting.
Patch testing can ferret out a trigger in atopic dermatitis patients with atypical disease distribution or refractory disease, and help avoid the need for systemic therapy, Dr. Silverman pointed out.
In the interview, he discussed these and other clinical scenarios, as well as how patch testing differs in these patients and what screening series to consider using.
Dr. Silverberg had no relevant financial disclosures.
SOURCE: Silverberg, J. et al, Session 061.
SAN DIEGO – Patch testing may be in order for some patients with atopic dermatitis, according to Jonathan Silverberg, MD, PhD, of the department of dermatology, Northwestern University, Chicago.
Allergic contact dermatitis is a common comorbid condition in people with AD “and sometimes, can flare up the severity of the disease,” he said in a video interview at the American Academy of Dermatology annual meeting.
Patch testing can ferret out a trigger in atopic dermatitis patients with atypical disease distribution or refractory disease, and help avoid the need for systemic therapy, Dr. Silverman pointed out.
In the interview, he discussed these and other clinical scenarios, as well as how patch testing differs in these patients and what screening series to consider using.
Dr. Silverberg had no relevant financial disclosures.
SOURCE: Silverberg, J. et al, Session 061.
SAN DIEGO – Patch testing may be in order for some patients with atopic dermatitis, according to Jonathan Silverberg, MD, PhD, of the department of dermatology, Northwestern University, Chicago.
Allergic contact dermatitis is a common comorbid condition in people with AD “and sometimes, can flare up the severity of the disease,” he said in a video interview at the American Academy of Dermatology annual meeting.
Patch testing can ferret out a trigger in atopic dermatitis patients with atypical disease distribution or refractory disease, and help avoid the need for systemic therapy, Dr. Silverman pointed out.
In the interview, he discussed these and other clinical scenarios, as well as how patch testing differs in these patients and what screening series to consider using.
Dr. Silverberg had no relevant financial disclosures.
SOURCE: Silverberg, J. et al, Session 061.
REPORTING FROM AAD 18
Video Report: CDER Stands by Position on Avastin
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
Video Report: CDER Stands by Position on Avastin
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
Video Report: CDER Stands by Position on Avastin
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
The first day of the Food and Drug Administration’s hearing on Avastin (bevacizumab) came to an end with a question-and-answer session between FDA officials and representatives from Genentech, the maker of the drug.
Earlier in the day, the Center for Drug Evaluation and Research (CDER) presented its position and stood by its proposal to withdraw approval for the breast cancer indication for Avastin.
Video Preview: FDA Hearing on Avastin
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.
Video Preview: FDA Hearing on Avastin
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.
During a two-day meeting at the Food and Drug Administration offices outside of Washington, Genentech will provide evidence to support the company’s contention that the metastatic breast cancer approval of bevacizumab, in combination with paclitaxel, should not be withdrawn.
In December, the FDA proposed that the accelerated approval for this indication be pulled after two studies failed to show the magnitude of benefit on progression-free survival seen in an earlier study. Moreover, none of the trials showed an improvement in overall survival.
In an unprecedented move, Genentech appealed the decision, and the FDA granted the company the hearing.